Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02070744 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation With an Open-Label Expansion
A Phase 2 study, sponsored by Vertex Pharmaceuticals Incorporated.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT02070744 is a Phase 2 study that has completed, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 40 participants.
The verdict
NCT02070744, a Phase 2 study, has completed, sponsored by Vertex Pharmaceuticals Incorporated.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
The objective of this study was to evaluate the safety and efficacy of VX-661in combination with ivacaftor in participants with cystic fibrosis (CF) who are homozygous for F508del cystic fibrosis transmembrane conductance regulator (CFTR) mutation
Interventions
- DRUG Ivacaftor
- DRUG Placebo matched to Ivacaftor
- DRUG VX-661
- DRUG Placebo matched to VX-661
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2014-03 |
| Est. Completion | 2016-05-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02070744
The ClinicalTrials.gov registry entry for NCT02070744 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Ivacaftor is the first listed.
NCT02070744 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02070744 about?
NCT02070744 is a clinical study titled "Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation With an Open-Label Expansion". The objective of this study was to evaluate the safety and efficacy of VX-661in combination with ivacaftor in participants with cystic fibrosis (CF) who are homozygous for F508del cystic fibrosis transmembrane conductance regulator (CFTR) mutation
What is the current status of trial NCT02070744?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2014-03. Estimated completion is 2016-05-27.
What interventions are being tested in trial NCT02070744?
The interventions under investigation include: Ivacaftor (DRUG), Placebo matched to Ivacaftor (DRUG), VX-661 (DRUG), Placebo matched to VX-661 (DRUG).
Who is sponsoring clinical trial NCT02070744?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.